Skip to main content
Premium Trial:

Request an Annual Quote

Protea, Mass General Partner on Cancer Immunotherapy Tests

NEW YORK (GenomeWeb) – Mass spectrometry instrument and services provider Protea Biosciences announced today that it has partnered with the the Massachusetts General Hospital (MGH) to develop new molecular tests to help guide cancer immunotherapies.

Under the terms of the deal, Protea will work with MGH's Vaccine and Immunotherapy Center to develop a diagnostic methodology for obtaining cancer cell molecular profiles, including the distribution of drugs within cancer cells and molecular response indicators.

"Our collective goal is to improve the molecular information rapidly available to patients and their physicians from tumor samples, which can be used as the basis for decisions regarding both the initiation and modification of specific immunotherapies for their treatment," Protea Chairman and CEO Steve Turner said in a statement.

Additional terms of the partnership were not disclosed.